A Tc-99m bicisate tracer used to see how blood reaches different areas of the brain after a confirmed stroke.
NeuroLite® is used after a confirmed stroke, when blood flow to part of the brain is disrupted. Its simple preparation, fast uptake, and flexible imaging window fit effectively into routine nuclear medicine workflows.1
NeuroLite® travels to the brain based on blood flow while clearing from the blood and non-target tissues faster. NeuroLite® is simple to prepare and helps produce clear, high-quality images that are easy to interpret by physicians.1
NeuroLite® single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed.
NeuroLite® is not indicated for assessment of functional viability of brain tissue or for distinguishing between stroke and other brain lesions.
None known.
In clinical trials, NeuroLite® has been administered to 1063 subjects (255 normals, 808 patients). In the 808 patients with neurologic events, there were 11 (1.4%) deaths, none of which were clearly attributed to NeuroLite®.
The following adverse effects were observed in ≤ 1% of the subjects: headache, dizziness, seizure, agitation/anxiety, malaise/somnolence, parosmia, hallucinations, rash, nausea, syncope, cardiac failure, hypertension, angina, and apnea/cyanosis.
None known.
USE WITH CAUTION IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT. TECHNETIUM Tc99m BICISATE IS ELIMINATED PRIMARILY BY RENAL EXCRETION. WHETHER TECHNETIUM Tc99m BICISATE IS DIALYZABLE IS NOT KNOWN. DOSE ADJUSTMENTS IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT HAVE NOT BEEN STUDIED.
Patients should be encouraged to drink fluids and to void frequently during the 2-6 hours immediately after injection to minimize radiation dose to the bladder and other target organs.
As with any other radioactive material, appropriate shielding should be used to avoid unnecessary radiation exposure to the patient, occupational workers, and other people.
Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides.
1. NeuroLite®. Prescribing Information. SHINE Technologies, LLC. 2019.
